Source comparison
Best SS-31 Dosage for Cardioprotection: Clinical Trial Comparison
EMBRACE STEMI (2020) Acute myocardial infarction 0.25 mg/kg single dose within 6 hours of PCI Subcutaneous 20% reduction in infarct size at 30-day MRI vs placebo (p<0.01) First trial to demonstrate tissue salvage with mitochondrial-targeted therapy. Single-dos
This comparison does not assign a generated winner or score.
- EMBRACE STEMI (2020)
- Acute myocardial infarction
- 0.25 mg/kg single dose within 6 hours of PCI
- Subcutaneous
- 20% reduction in infarct size at 30-day MRI vs placebo (p<0.01)
- First trial to demonstrate tissue salvage with mitochondrial-targeted therapy. Single-dose protocol limits compliance issues
- HFpEF Phase 2 (Circulation, 2019)
- Heart failure with preserved ejection fraction
- 0.25 mg/kg daily for 4 weeks
- +38 meters six-minute walk distance; 18% reduction in NT-proBNP
- Daily dosing showed cumulative benefit. Suggests chronic mitochondrial dysfunction responds to sustained cardiolipin stabilization
- QUEST (2021)
- Primary mitochondrial myopathy
- 0.5 mg/kg daily for 28 days
- No significant change in exercise capacity vs placebo
- Higher dose didn't overcome genetic Complex I deficiency. Confirms SS-31 works via cristae stabilization, not bypassing electron transport defects
- Barth Syndrome Trial (2018)
- Cardiolipin deficiency disorder
- 0.25 mg/kg daily for 12 weeks
- 12% improvement in left ventricular ejection fraction (exploratory endpoint)
- Small sample (n=12) but promising in genetic cardiolipin disorder. Mechanistically logical given SS-31's cardiolipin-binding mechanism